Hvsen Biotechnology Future Growth
Future criteria checks 5/6
Hvsen Biotechnology is forecast to grow earnings and revenue by 60.4% and 21% per annum respectively. EPS is expected to grow by 60.5% per annum. Return on equity is forecast to be 8.1% in 3 years.
Key information
60.4%
Earnings growth rate
60.5%
EPS growth rate
Pharmaceuticals earnings growth | 18.4% |
Revenue growth rate | 21.0% |
Future return on equity | 8.1% |
Analyst coverage | Low |
Last updated | 29 Apr 2024 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,801 | 128 | 227 | 269 | 2 |
12/31/2025 | 1,566 | 137 | 116 | 201 | 2 |
12/31/2024 | 1,246 | 68 | -79 | 147 | 2 |
3/31/2024 | 996 | -14 | -139 | 64 | N/A |
12/31/2023 | 1,020 | 17 | -91 | 93 | N/A |
9/30/2023 | 1,043 | 41 | -167 | 80 | N/A |
6/30/2023 | 1,075 | 62 | -225 | 77 | N/A |
3/31/2023 | 1,048 | 66 | -257 | 96 | N/A |
1/1/2023 | 1,023 | 53 | -332 | 97 | N/A |
9/30/2022 | 922 | 40 | -320 | 109 | N/A |
6/30/2022 | 857 | 38 | -471 | 120 | N/A |
3/31/2022 | 888 | 71 | -488 | 160 | N/A |
1/1/2022 | 996 | 133 | -444 | 156 | N/A |
9/30/2021 | 1,027 | 173 | -447 | 125 | N/A |
6/30/2021 | 1,026 | 199 | -319 | 88 | N/A |
3/31/2021 | 956 | 188 | -277 | 17 | N/A |
12/31/2020 | 777 | 150 | -182 | 48 | N/A |
9/30/2020 | 655 | 130 | -97 | 111 | N/A |
12/31/2019 | 427 | 69 | -18 | 105 | N/A |
12/31/2018 | 422 | 71 | -13 | 21 | N/A |
12/31/2017 | 400 | 88 | N/A | 81 | N/A |
12/31/2016 | 258 | 49 | N/A | 60 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300871 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).
Earnings vs Market: 300871 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 300871 is expected to become profitable in the next 3 years.
Revenue vs Market: 300871's revenue (21% per year) is forecast to grow faster than the CN market (13.5% per year).
High Growth Revenue: 300871's revenue (21% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300871's Return on Equity is forecast to be low in 3 years time (8.1%).